KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ...

Timing and uptake of germline testing in patients with somatic BRCA1/2 pathogenic or likely pathogenic variants in solid tumors: A real-world study from community oncology practices. Identifying ...

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Prostate cancer highlights from the American Urological Association 2025 meeting include quality-of-life results from the phase 3 PSMAfore study, findings on androgen deprivation therapy (ADT) with or ...

CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...

An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...

One of the most common concerns about treating prostate cancer is preserving sexual function and urinary control. For some prostate cancers, newer treatments offering an alternative to radiation and ...

Northampton Prostate Cancer Support Group have organised an event on Saturday May 16 at Northampton College, Booth Lane, at ...